Introduction

Tivicay is the brand name for dolutegravir, an HIV medicine that sits at the heart of GSK plc's (LSE:GSK) HIV franchise. It is marketed by ViiV Healthcare, the specialist HIV company that GSK majority-owns. In the UK it is approved, in combination with other antiretroviral medicines, for adults, adolescents and children aged at least six years and weighing at least 14 kg, according to its approved product information.

For investors, Tivicay matters less as a single product line and more as the active substance that anchors a broader dolutegravir portfolio, including the two-drug regimen Dovato. Following a January 2026 agreement completed around April 2026, GSK retains a 78.3% economic interest in ViiV, Shionogi holds 21.7% and Pfizer has exited. This article examines what Tivicay is, how it works, its approved uses, the ownership structure, competition, generic risk and what investors may wish to monitor.

What is Tivicay?

Tivicay is the brand name for dolutegravir, a prescription antiretroviral medicine used in the treatment of HIV. In the UK it is available as 50 mg film-coated tablets, with a paediatric formulation also part of the dolutegravir range. It is authorised and marketed through ViiV Healthcare, GSK plc's majority-owned HIV company.

Tivicay is a single-agent (monocomponent) product, meaning it contains dolutegravir as its only active substance. It is designed to be used alongside other antiretroviral medicines rather than as a standalone therapy. This distinguishes it from fixed-dose combination products such as Dovato, which pair dolutegravir with a second active substance in one tablet.

Tivicay was first approved in the United States in 2013 and in the European Union in 2014, establishing dolutegravir as one of the more widely used integrase inhibitors in modern HIV care. It remains a currently approved, marketed medicine across the UK, EU and US, with no evidence of withdrawal or suspension.

How does dolutegravir work?

Dolutegravir belongs to a class of antiretrovirals known as integrase strand transfer inhibitors, or INSTIs. According to the Tivicay Summary of Product Characteristics, it binds to the active site of HIV integrase and blocks the strand-transfer step of retroviral DNA integration, a step that is essential to the HIV replication cycle.

By interrupting integration, dolutegravir helps prevent the virus from inserting its genetic material into host cells, which supports suppression of viral replication when used as part of a combination regimen. This mechanism is why dolutegravir is almost always prescribed alongside other antiretroviral agents that act on different stages of the viral life cycle.

In the Dovato combination, dolutegravir is paired with lamivudine, a nucleoside reverse transcriptase inhibitor. According to Dovato's approved product information, lamivudine's active triphosphate incorporates into viral DNA and causes chain termination, providing a complementary mechanism within a two-drug regimen.

What indications are approved?

In the UK, Tivicay is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-infected adults, adolescents and children of at least six years of age and weighing at least 14 kg, according to its emc Summary of Product Characteristics accessed on 14 July 2026. Its broad paediatric-to-adult eligibility is a notable feature of the product.

Dovato, the dolutegravir/lamivudine fixed-dose regimen, is separately indicated in the UK for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class or to lamivudine. These are distinct products with distinct indications and should not be conflated.

Indications and eligibility criteria can differ by region and must not be merged across jurisdictions. In the US, for example, the paediatric weight thresholds and treatment-history conditions attached to these products differ from the UK wording; readers should consult the current FDA and EMA labels for region-specific detail rather than assume UK criteria apply elsewhere.

What is GSK's relationship with ViiV Healthcare?

ViiV Healthcare is a specialist HIV company that is majority-owned by GSK plc. Tivicay and Dovato are marketed through ViiV, with ViiV Healthcare UK Ltd acting as the GB marketing authorisation holder and ViiV Healthcare BV holding the EU centralised authorisations. This means Tivicay's commercial performance flows into GSK's results through its ownership of ViiV.

The ownership structure changed materially in 2026. Under an agreement announced on 20 January 2026 and completed around 1 April 2026, Pfizer exited ViiV entirely, Shionogi increased its stake to 21.7% and GSK retained a 78.3% economic interest. Previously, the holding had been split approximately GSK 78.3%, Pfizer 11.7% and Shionogi 10%.

According to GSK's press release, the transaction involved ViiV issuing new shares to Shionogi for USD 2.125bn consideration and cancelling Pfizer's holding, with Pfizer receiving USD 1.875bn and GSK a special dividend of USD 0.250bn. GSK therefore continues to control ViiV, while Shionogi's larger minority interest is a governance factor investors may note.

How does Tivicay fit alongside combination products?

Tivicay's strategic importance lies partly in the fact that dolutegravir is the shared backbone of several ViiV products. As the monocomponent, Tivicay provides flexibility in tailoring combination regimens, particularly across paediatric and adult populations and in patients who may need bespoke drug combinations.

Dovato takes the same molecule and packages it with lamivudine as a two-drug, single-tablet regimen aimed at simplifying therapy. Alongside these sit other dolutegravir-based products in the ViiV portfolio, such as Triumeq and Juluca, and the long-acting injectable Cabenuva (cabotegravir/rilpivirine), which addresses a different administration format.

This portfolio breadth means the value of dolutegravir to GSK is greater than any single brand's sales. It also creates internal dynamics: growth in newer regimens or long-acting formats can shift demand between ViiV's own products. Where product-level revenue is not separately disclosed, investors should refer to GSK's quarterly results and annual report rather than estimate.

What competition and generic risks exist?

The most prominent competitor to ViiV's oral dolutegravir regimens is Gilead Sciences' Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a leading single-tablet integrase inhibitor regimen, together with Gilead's broader range of TAF-based products such as Genvoya, Descovy and Odefsey. Merck & Co also competes with doravirine-based products including Delstrigo and Pifeltro, and has an islatravir-based pipeline.

Format competition is a further dynamic. The gradual shift from daily oral tablets toward long-acting injectables, including ViiV's own Cabenuva, could over time influence demand for oral dolutegravir regimens. This is both a competitive threat and, given ViiV's injectable presence, an internal portfolio consideration.

On generics, Tivicay and Dovato remain on-patent in the US and EU, with no FDA- or EMA-approved branded-market generic identified. However, generic dolutegravir-based fixed-dose combinations, notably the TLD regimen (tenofovir disoproxil/lamivudine/dolutegravir), are widely available in low- and middle-income countries through voluntary licensing arrangements such as the Medicines Patent Pool. Longer term, patent expiry and generic erosion represent a structural risk to the franchise.

How large is the addressable market?

HIV treatment is a large, chronic and long-established therapeutic area, with sustained global demand driven by lifelong treatment needs and continued efforts to expand access. GSK describes HIV as a core franchise within its Specialty Medicines segment, and the dolutegravir portfolio is a material contributor to group revenue.

This article does not reproduce specific revenue, market-share, growth or efficacy figures, because those could not be re-verified against a primary GSK disclosure in this session. Such figures should be taken directly from GSK's latest results announcement or annual report rather than estimated.

Qualitatively, the durability of dolutegravir demand reflects its widespread use across guidelines and populations. Commercial performance will nonetheless depend on competitive positioning, pricing and reimbursement outcomes, and the evolving mix between oral and long-acting formats.

What should investors monitor?

Investors may wish to monitor GSK's quarterly results for disclosure on the HIV franchise, including how dolutegravir-based products perform against competitors such as Biktarvy. Momentum in Dovato and the broader oral portfolio, alongside uptake of long-acting Cabenuva, offers a read on how ViiV is balancing its formats.

Ownership and governance are also relevant following the 2026 shareholding changes. GSK's continued 78.3% control provides stability, but Shionogi's increased 21.7% minority interest and Pfizer's full exit reshape the shareholder base. Investors may track how this affects ViiV's strategy and any minority-interest considerations in GSK's accounts.

Other areas to watch include pricing and reimbursement pressure from bodies such as NICE and the NHS and from US payers, the trajectory of generic dolutegravir in international markets, and any regulatory or pharmacovigilance developments. The historical dolutegravir neural-tube-defect safety signal and associated labelling illustrate the type of safety and litigation risk that can affect established medicines. Pipeline progress on next-generation regimens will also matter.

It is worth noting that a presence in a regulatory substance index only evidences that product files exist; it is not, by itself, proof of new approval, ownership change, launch or commercial success. Investors should rely on primary company and regulatory disclosures.